ITM: the radiopharmaceutical company that has all the answers in a challenging field

Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies.

Since its foundation in 2004, the German company has also helped to drive the wider growth of radiopharmaceutical therapy class of cancer therapeutics, becoming a pioneer and collaborator with scientific, medical and industrial partners worldwide.

Nowhere more is that apparent than through its relationship with Novartis (NOVN: VX). The Munich firm provides radioisotopes for the Swiss pharma giant’s approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which is seen as an important frontrunner in the field. But ITM is also competing with the Basel-based company on the drug development front.